Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156543153> ?p ?o ?g. }
- W2156543153 endingPage "31" @default.
- W2156543153 startingPage "23" @default.
- W2156543153 abstract "According to international treatment guidelines, inhaled rapid-acting β2 agonists should be used for the control of symptoms in patients with asthma. We compared the efficacy and safety of an extrafine combination inhaler containing a corticosteroid (beclometasone) plus a rapid-onset, long-acting β2 agonist (formoterol) with a short-acting β2 agonist (salbutamol) as reliever strategies in patients taking beclometasone-formoterol combination as maintenance treatment.In a double-blind trial undertaken in 183 centres in 14 European countries over 48 weeks, patients (aged ≥18 years) with asthma that was not fully controlled, with a forced expiratory volume in 1 s (FEV1) of at least 60% predicted, had a 2-week run in. During this period, patients were treated with a combination of beclometasone 100 μg and formoterol 6 μg per one inhalation twice daily plus salbutamol 100 μg as required delivered by use of a pressurised metered-dose inhaler. They were then randomly assigned in a 1:1 ratio with a computer-generated randomisation list to receive beclometasone 100 μg plus formoterol 6 μg or salbutamol 100 μg as reliever in addition to maintenance with beclometasone 100 μg plus formoterol 6 μg twice daily. Primary outcome was the time to first severe exacerbation (admission to hospital or visit to emergency department, or use of systemic steroids for ≥3 consecutive days). Secondary outcomes were number of severe exacerbations (events per 100 patients per year), time to and number of mild exacerbations, additional exacerbation variables, lung function, symptom scores, and asthma control. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, number NCT00861926.1714 patients were randomly assigned to the as-needed beclometasone-formoterol (n=857) and as-needed salbutamol groups (n=857), and 1701 were analysed (852 and 849, respectively). 326 severe exacerbations were reported by 251 patients during the study, and 99 versus 152 patients had at least one exacerbation during the 48 weeks, respectively. Compared with beclometasone-formoterol plus salbutamol as needed, beclometasone-formoterol for both maintenance and reliever treatment significantly increased the time to first exacerbation (209 days vs 134 days) by 75 days, with a 36% reduction in risk (hazard ratio 0·64 [95% CI 0·49 to 0·82]; p=0·0005), and the estimated probability was 12% and 18%, respectively (p=0·0003). The number of days with mild asthma exacerbations was also lower with as-needed beclometasone-formoterol than with as-needed salbutamol (56·04 days per patient per year vs 65·11 days per patient per year; 0·86 [0·76 to 0·98]; p=0·021). From the run-in period to week 48, both treatments improved symptoms (mean change -1·59 [-1·94 to -1·25] in the as-needed beclometasone-formoterol group vs -1·44 [-1·78 to -1·10] in the as-needed salbutamol group, difference -0·15 [-0·60 to 0·30]; p=0·507), percentage of asthma control days (9·5% [7·3 to 11·8] vs 10·9% [8·7 to 13·1], respectively, -1·4 [-4·3 to 1·6]; p=0·359), use of reliever (-0·29 [-0·38 to -0·20] vs -0·27 [-0·36 to -0·19], respectively, -0·02 [-0·13 to 0·10]; p=0·794), and lung function (FEV1, 0·090 [0·060 to 0·120] vs 0·090 [0·060-0·120], respectively, 0·001 [-0·040 to 0·040]; p=0·969), and were well tolerated (patients with serious adverse events, 32 [4%] and 41 [5%], respectively).Our results lend support to the use of the combination of a single inhaled corticosteroid plus a rapid-onset, long-acting β2 agonist for maintenance and relief in patients with moderate to severe asthma and provide encouraging data for the formulation of beclometasone-formoterol for this use.Chiesi Farmaceutici." @default.
- W2156543153 created "2016-06-24" @default.
- W2156543153 creator A5010278392 @default.
- W2156543153 creator A5016161340 @default.
- W2156543153 creator A5018753599 @default.
- W2156543153 creator A5020607400 @default.
- W2156543153 creator A5028265360 @default.
- W2156543153 creator A5045751851 @default.
- W2156543153 creator A5046019803 @default.
- W2156543153 creator A5089847016 @default.
- W2156543153 date "2013-03-01" @default.
- W2156543153 modified "2023-10-14" @default.
- W2156543153 title "Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial" @default.
- W2156543153 cites W1785989671 @default.
- W2156543153 cites W1985171602 @default.
- W2156543153 cites W1985851375 @default.
- W2156543153 cites W2011267749 @default.
- W2156543153 cites W2021023200 @default.
- W2156543153 cites W2038850183 @default.
- W2156543153 cites W2043435391 @default.
- W2156543153 cites W2065707788 @default.
- W2156543153 cites W2071252658 @default.
- W2156543153 cites W2076025700 @default.
- W2156543153 cites W2083757777 @default.
- W2156543153 cites W2088384625 @default.
- W2156543153 cites W2101885173 @default.
- W2156543153 cites W2103849655 @default.
- W2156543153 cites W2107742493 @default.
- W2156543153 cites W2110658984 @default.
- W2156543153 cites W2112649669 @default.
- W2156543153 cites W2116458407 @default.
- W2156543153 cites W2118957675 @default.
- W2156543153 cites W2126411802 @default.
- W2156543153 cites W2131336668 @default.
- W2156543153 cites W2131393016 @default.
- W2156543153 cites W2141960005 @default.
- W2156543153 cites W2148164742 @default.
- W2156543153 cites W2150699501 @default.
- W2156543153 cites W2153236387 @default.
- W2156543153 cites W2601675613 @default.
- W2156543153 cites W4245552987 @default.
- W2156543153 doi "https://doi.org/10.1016/s2213-2600(13)70012-2" @default.
- W2156543153 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24321801" @default.
- W2156543153 hasPublicationYear "2013" @default.
- W2156543153 type Work @default.
- W2156543153 sameAs 2156543153 @default.
- W2156543153 citedByCount "118" @default.
- W2156543153 countsByYear W21565431532013 @default.
- W2156543153 countsByYear W21565431532014 @default.
- W2156543153 countsByYear W21565431532015 @default.
- W2156543153 countsByYear W21565431532016 @default.
- W2156543153 countsByYear W21565431532017 @default.
- W2156543153 countsByYear W21565431532018 @default.
- W2156543153 countsByYear W21565431532019 @default.
- W2156543153 countsByYear W21565431532020 @default.
- W2156543153 countsByYear W21565431532021 @default.
- W2156543153 countsByYear W21565431532022 @default.
- W2156543153 countsByYear W21565431532023 @default.
- W2156543153 crossrefType "journal-article" @default.
- W2156543153 hasAuthorship W2156543153A5010278392 @default.
- W2156543153 hasAuthorship W2156543153A5016161340 @default.
- W2156543153 hasAuthorship W2156543153A5018753599 @default.
- W2156543153 hasAuthorship W2156543153A5020607400 @default.
- W2156543153 hasAuthorship W2156543153A5028265360 @default.
- W2156543153 hasAuthorship W2156543153A5045751851 @default.
- W2156543153 hasAuthorship W2156543153A5046019803 @default.
- W2156543153 hasAuthorship W2156543153A5089847016 @default.
- W2156543153 hasConcept C126322002 @default.
- W2156543153 hasConcept C2776042228 @default.
- W2156543153 hasConcept C2776136866 @default.
- W2156543153 hasConcept C2776178081 @default.
- W2156543153 hasConcept C2777014857 @default.
- W2156543153 hasConcept C2777394947 @default.
- W2156543153 hasConcept C2777714996 @default.
- W2156543153 hasConcept C2777992530 @default.
- W2156543153 hasConcept C2779871671 @default.
- W2156543153 hasConcept C2780261241 @default.
- W2156543153 hasConcept C2781018748 @default.
- W2156543153 hasConcept C42219234 @default.
- W2156543153 hasConcept C71924100 @default.
- W2156543153 hasConceptScore W2156543153C126322002 @default.
- W2156543153 hasConceptScore W2156543153C2776042228 @default.
- W2156543153 hasConceptScore W2156543153C2776136866 @default.
- W2156543153 hasConceptScore W2156543153C2776178081 @default.
- W2156543153 hasConceptScore W2156543153C2777014857 @default.
- W2156543153 hasConceptScore W2156543153C2777394947 @default.
- W2156543153 hasConceptScore W2156543153C2777714996 @default.
- W2156543153 hasConceptScore W2156543153C2777992530 @default.
- W2156543153 hasConceptScore W2156543153C2779871671 @default.
- W2156543153 hasConceptScore W2156543153C2780261241 @default.
- W2156543153 hasConceptScore W2156543153C2781018748 @default.
- W2156543153 hasConceptScore W2156543153C42219234 @default.
- W2156543153 hasConceptScore W2156543153C71924100 @default.
- W2156543153 hasIssue "1" @default.
- W2156543153 hasLocation W21565431531 @default.
- W2156543153 hasLocation W21565431532 @default.
- W2156543153 hasOpenAccess W2156543153 @default.
- W2156543153 hasPrimaryLocation W21565431531 @default.